Association study of SNAP25 and schizophrenia in Irish family and case-control samples.
SNAP25 occurs on chromosome 20p12.2, which has been linked to schizophrenia in some samples, and recently linked to latent classes of psychotic illness in our sample. SNAP25 is crucial to synaptic functioning, may be involved in axonal growth and dendritic sprouting, and its expression may be decreased in schizophrenia. We genotyped 18 haplotype-tagging SNPs in SNAP25 in a sample of 270 Irish high-density families. Single marker and haplotype analyses were performed in FBAT and PDT. We adjusted for multiple testing by computing q values. Association was followed up in an independent sample of 657 cases and 411 controls. We tested for allelic effects on the clinical phenotype by using the method of sequential addition and 5 factor-derived scores of the OPCRIT. Nine of 18 SNPs had P values <0.05 in either FBAT or PDT for one or more definitions of illness. Several two-marker haplotypes were also associated. Subjects inheriting the risk alleles of the most significantly associated two-marker haplotype were likely to have higher levels of hallucinations and delusions. The most significantly associated marker, rs6039820, was observed to perturb 12 transcription-factor binding sites in in silico analyses. An attempt to replicate association findings in the case-control sample resulted in no SNPs being significantly associated. We observed robust association in both single marker and haplotype-based analyses between SNAP25 and schizophrenia in an Irish family sample. Although we failed to replicate this in an independent sample, this gene should be further tested in other samples.
Fanous
A H
AH
Washington VA Medical Center, Washington, District of Columbia.|Georgetown University Medical Center, Virginia Commonwealth University, Richmond, Virginia.|Department of Psychiatry, Virginia Commonwealth University, Richmond, Virginia.
Zhao
Z
Z
Departments of Biomedical Informatics and Psychiatry, Vanderbilt University, Nashville, Tennessee.
van den Oord
E J C G
EJCG
Department of Psychiatry, Virginia Commonwealth University, Richmond, Virginia.|Department of Pharmacy, Virginia Commonwealth University, Richmond, Virginia.
Maher
B S
BS
Department of Psychiatry, Virginia Commonwealth University, Richmond, Virginia.
Thiselton
D L
DL
Department of Psychiatry, Virginia Commonwealth University, Richmond, Virginia.
Bergen
S E
SE
Department of Psychiatry, Virginia Commonwealth University, Richmond, Virginia.
Wormley
B
B
Department of Psychiatry, Virginia Commonwealth University, Richmond, Virginia.
Bigdeli
T
T
Department of Psychiatry, Virginia Commonwealth University, Richmond, Virginia.
Amdur
R L
RL
Washington VA Medical Center, Washington, District of Columbia.|Georgetown University Medical Center, Virginia Commonwealth University, Richmond, Virginia.
O'Neill
F A
FA
Queen's University, Belfast, UK.
Walsh
D
D
Health Research Board, Dublin, Ireland.
Kendler
K S
KS
Department of Psychiatry, Virginia Commonwealth University, Richmond, Virginia.|Department of Human Genetics, Virginia Commonwealth University, Richmond, Virginia.
Riley
B P
BP
Department of Psychiatry, Virginia Commonwealth University, Richmond, Virginia.|Department of Human Genetics, Virginia Commonwealth University, Richmond, Virginia.
D000483:Alleles; D001369:Axons; D016022:Case-Control Studies; D003712:Dendrites / Q000473:pathology; D005192:Family Health; D005819:Genetic Markers; D006239:Haplotypes; D006801:Humans; D007494:Ireland; D008957:Models, Genetic; D010641:Phenotype; D011110:Polymorphism, Genetic; D012559:Schizophrenia / Q000235:genetics*; D050825:Synaptosomal-Associated Protein 25 / Q000235:genetics*
D005819:Genetic Markers; C494208:SNAP25 protein, human; D050825:Synaptosomal-Associated Protein 25